Study had insufficient power to investigate safety

BMJ (Online)

Volumn 345, Issue 7886, 2012, Pages

  Rossouw, Jacques E ^a   Manson, JoAnn E ^b   Kaunitz, Andrew M ^c   Stefanick, Marcia L ^d  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO;

AGE DISTRIBUTION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; HEART DEATH; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LETTER; MONOTHERAPY; MORTALITY; OPEN STUDY; OUTCOME ASSESSMENT; POWER ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; THROMBOEMBOLISM; WOMEN'S HEALTH;

FEMALE; HEART FAILURE; HORMONE REPLACEMENT THERAPY; HUMANS; MYOCARDIAL INFARCTION; NEOPLASMS;

EID: 84870686763     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e8146     Document Type: Letter

References (3)

1. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409. (9 October.)
2. Mosekilde L, Hermann AP, Beck-Nielsen H, Charles P, Nielsen SP, Sorensen OH. The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 1999;31:207-19. (Pubitemid 29132822)
3. Rossouw JE, Prentice RL, Manson JE, Wu LL, Barad D, Barnabei VM, et al. Post menopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77. (Pubitemid 46556472)